Search Results

the poor outcomes associated with BRAF mt mCRC. Although potential improvement in survival with FOLFOXIRI has been suggested, current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer (Version 4.2020) still do not give

study of a large, contemporary national database of a general US population aimed to evaluate national practice patterns and outcomes of unresected nonmetastatic GC receiving CT alone versus CRT. Although challenging to assess with single- or multi

provide the convenience for self-medication at home; however, they increase the risks for nonadherence, drug interactions, and adverse drug events (ADEs), which may threaten therapeutic outcomes and patient safety. 2 Oral chemotherapy drugs are perceived

, evaluating CIPN with a valid, reliable, and responsive outcome measure is critical in identifying early signs of nerve damage and effects of intervention aimed at preventing long-lasting or severe neurotoxicity. There are numerous approaches to assessing

to have much poorer outcomes with single-agent immunotherapy. PD-L1 Expression ≥50% In KEYNOTE-024, pembrolizumab more than doubled median overall survival (mOS) compared with chemotherapy for patients with PD-L1 expression ≥50%, improving mOS to 30

outcomes of hospitalized patients with cancer in terms of infection, mortality, length of stay, and toxicities. The risk of cancer death (from stomach, liver, lung cancers) has been noted to be significantly higher among those with a high fasting plasma

data addressing management of this rare malignancy, we used the National Cancer Database (NCDB) to assess survival outcomes according to stage and treatment strategy in patients with anal adenocarcinoma. We focused our investigation on a comparison of

measurement have been used to address this problem by clearly delineating best practices. 2 Although many improvement efforts have centered on the coordination of outpatient care services, there are few studies of in-hospital care processes and their outcomes

-adjusted incidence of vSCC is 2.5 per 100,000 women. 3 The most significant prognostic factor for vSCC is lymph node status. 4 , 5 Other factors associated with poor outcomes include age, tumor diameter, tumor depth, tumor class, histologic grade, lymphovascular

-center, retrospective study, we evaluated PCA use and associated clinical outcomes in patients admitted to the hospital with cancer-related pain, defined as acute or chronic physical pain attributed to cancer or its treatment. Methods Study Cohort All